Trial reportPloS one2012
A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.
Trial report in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 5 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Pooled it
- A Review ofNutrients · 2019Pooled it
- A review of dietary selenium intake and selenium status in Europe and the Middle East.Nutrients · 2015Pooled it
- Selenium supplementation and the risk of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.Endocrine · 2014Pooled it
- Selenium supplementation for the primary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2013Pooled it
- Effect of selenium supplementation on musculoskeletal health in older women: a randomised, double-blind, placebo-controlled trial.The lancet. Healthy longevity · 2021Trial
- The Effect of Iranian Propolis on Glucose Metabolism, Lipid Profile, Insulin Resistance, Renal Function and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind Clinical Trial.Scientific reports · 2019Trial
- Serum Selenium Levels and Their Relationship with Insulin Resistance in Individuals with Polycystic Ovary Syndrome.Biological trace element research · 2025Article
- Association Between Selenium and Circulating Adipokine Levels in Patients with Polycystic Ovary Syndrome.Biological trace element research · 2024Article
- Selenium status and its determinants in very old adults: insights from the Newcastle 85+ Study.The British journal of nutrition · 2024Article
- Article
- Scientific opinion on the tolerable upper intake level for selenium.EFSA journal. European Food Safety Authority · 2023Article
- Association Between Serum Selenium Concentration and OPG/RANKL/RANK Axis in Patients with Arterial Hypertension.Cardiovascular toxicology · 2022Article
- Selenium and Selenoproteins at the Intersection of Type 2 Diabetes and Thyroid Pathophysiology.Antioxidants (Basel, Switzerland) · 2022Review
- The role of selenium in type-2 diabetes mellitus and its metabolic comorbidities.Redox biology · 2022Review
- Nutrient-Optimized Beef Enhances Blood Levels of Vitamin D and Selenium among Young Women.Foods (Basel, Switzerland) · 2022Article
- Emerging roles of selenium on metabolism and type 2 diabetes.Frontiers in nutrition · 2022Review
- The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves' Ophthalmopathy.Biomedicines · 2021Review
- Selenomethionine modulates insulin secretion in the MIN6-K8 mouse insulinoma cell line.FEBS letters · 2021Article
- Toxicology and pharmacology of synthetic organoselenium compounds: an update.Archives of toxicology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundEvidence that selenium affects the risk of type-2 diabetes is conflicting, with observational studies and a few randomized trials showing both lower and higher risk linked to the level of selenium intake and status. We investigated the effect of selenium supplementation on the risk of type-2 diabetes in a population of relatively low selenium status as part of the UK PRECISE (PREvention of Cancer by Intervention with SElenium) pilot study. Plasma adiponectin concentration, a recognised independent predictor of type-2 diabetes risk and known to be correlated with circulating selenoprotein P, was the biomarker chosen.
methodsIn a randomized, double-blind, placebo-controlled trial, five hundred and one elderly volunteers were randomly assigned to a six-month intervention with 100, 200 or 300 µg selenium/d as high-selenium or placebo yeast. Adiponectin concentration was measured by ELISA at baseline and after six months of treatment in 473 participants with one or both plasma samples available.
resultsMean (SD) plasma selenium concentration was 88.5 ng/g (19.1) at baseline and increased significantly in the selenium-treatment groups. In baseline cross-sectional analyses, the fully adjusted geometric mean of plasma adiponectin was 14% lower (95% CI, 0-27%) in the highest than in the lowest quartile of plasma selenium (P for linear trend = 0.04). In analyses across randomized groups, however, selenium supplementation had no effect on adiponectin levels after six months of treatment (P = 0.96).
conclusionsThese findings are reassuring as they did not show a diabetogenic effect of a six-month supplementation with selenium in this sample of elderly individuals of relatively low selenium status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.